mechanism of action combidex in mr imaging mukesh harisinghani, md department of radiology,...
TRANSCRIPT
![Page 1: Mechanism of Action Combidex in MR Imaging Mukesh Harisinghani, MD Department of Radiology, Massachusetts General Hospital](https://reader030.vdocument.in/reader030/viewer/2022032702/56649ce55503460f949b21a9/html5/thumbnails/1.jpg)
Mechanism of Action Combidex in MR Imaging
Mukesh Harisinghani, MD
Department of Radiology,
Massachusetts General Hospital
![Page 2: Mechanism of Action Combidex in MR Imaging Mukesh Harisinghani, MD Department of Radiology, Massachusetts General Hospital](https://reader030.vdocument.in/reader030/viewer/2022032702/56649ce55503460f949b21a9/html5/thumbnails/2.jpg)
2
Overview
Current limitations for LN staging in cancer
Combidex enhanced MRI Mechanism of action
Fulfills unmet clinical need of staging LN in patientswith known primary cancer
![Page 3: Mechanism of Action Combidex in MR Imaging Mukesh Harisinghani, MD Department of Radiology, Massachusetts General Hospital](https://reader030.vdocument.in/reader030/viewer/2022032702/56649ce55503460f949b21a9/html5/thumbnails/3.jpg)
3
Why Image Lymph Nodes?
Accurate staging of the primary cancer
Appropriate treatment
Prostate Cancer
LN Positive Treatment changed to non-surgical
Get a sense of the prognosis
Bladder Cancer
Node Negative 10-year survival 57–87%
Node Positive 5-year survival 35–38%
Risk of death increases 20% with each additional + LN
Cheville et al. Cancer 97, 2003.
![Page 4: Mechanism of Action Combidex in MR Imaging Mukesh Harisinghani, MD Department of Radiology, Massachusetts General Hospital](https://reader030.vdocument.in/reader030/viewer/2022032702/56649ce55503460f949b21a9/html5/thumbnails/4.jpg)
4
Current LN Staging
Non-InvasiveNon-Invasive
ImagingImaging
InvasiveInvasive
Surgical LN Sampling (gold standard)Surgical LN Sampling (gold standard)
![Page 5: Mechanism of Action Combidex in MR Imaging Mukesh Harisinghani, MD Department of Radiology, Massachusetts General Hospital](https://reader030.vdocument.in/reader030/viewer/2022032702/56649ce55503460f949b21a9/html5/thumbnails/5.jpg)
5
Size Criteria
< 10 mm< 10 mm
< 8 mm< 8 mm
BenignBenign
> 10 mm> 10 mm
> 8 mm> 8 mm
MalignantMalignant
![Page 6: Mechanism of Action Combidex in MR Imaging Mukesh Harisinghani, MD Department of Radiology, Massachusetts General Hospital](https://reader030.vdocument.in/reader030/viewer/2022032702/56649ce55503460f949b21a9/html5/thumbnails/6.jpg)
BenignBenign MalignantMalignant
18 mm in short axis 5 mm in short axis
Size criterion is inaccurateSize criterion is inaccurate
![Page 7: Mechanism of Action Combidex in MR Imaging Mukesh Harisinghani, MD Department of Radiology, Massachusetts General Hospital](https://reader030.vdocument.in/reader030/viewer/2022032702/56649ce55503460f949b21a9/html5/thumbnails/7.jpg)
Morphology – Fatty Hilum
MalignantMalignantBenignBenign
![Page 8: Mechanism of Action Combidex in MR Imaging Mukesh Harisinghani, MD Department of Radiology, Massachusetts General Hospital](https://reader030.vdocument.in/reader030/viewer/2022032702/56649ce55503460f949b21a9/html5/thumbnails/8.jpg)
8
Morphology – Central Necrosis
CT in Cervical Cancer
Positive predictive valueof 100% for nodal metastases
Most necrotic nodes haddiameter > 2 cm
Yang et al. AJR 2000;175.
![Page 9: Mechanism of Action Combidex in MR Imaging Mukesh Harisinghani, MD Department of Radiology, Massachusetts General Hospital](https://reader030.vdocument.in/reader030/viewer/2022032702/56649ce55503460f949b21a9/html5/thumbnails/9.jpg)
9
Pelvic Lymphadenectomy
Pelvic lymph node dissection (PLND) accompanied by frozen section pathological examination
Standard pelvic lymphadenectomyis limited
Extended pelvic lymphadenectomy
Incidence of lymph node metastases increased from 10% to 26.2%
Heidenreich et al. J Urol. April 2002.
![Page 10: Mechanism of Action Combidex in MR Imaging Mukesh Harisinghani, MD Department of Radiology, Massachusetts General Hospital](https://reader030.vdocument.in/reader030/viewer/2022032702/56649ce55503460f949b21a9/html5/thumbnails/10.jpg)
Extended lymph node dissection Obturator nerve injury Trauma to major vessels
Narayan et al. Urology 1994;44:519–24.
Frozen section pathologic analysis has false negative rate of 30–40%
Young et al. J Clin Path 52,1999.
![Page 11: Mechanism of Action Combidex in MR Imaging Mukesh Harisinghani, MD Department of Radiology, Massachusetts General Hospital](https://reader030.vdocument.in/reader030/viewer/2022032702/56649ce55503460f949b21a9/html5/thumbnails/11.jpg)
11
Current Need
Non-invasive techniqueNon-invasive technique that detects andcharacterizes LN with high degreeof sensitivity and specificity
Broad anatomic coverageBroad anatomic coverage for all LN
![Page 12: Mechanism of Action Combidex in MR Imaging Mukesh Harisinghani, MD Department of Radiology, Massachusetts General Hospital](https://reader030.vdocument.in/reader030/viewer/2022032702/56649ce55503460f949b21a9/html5/thumbnails/12.jpg)
Combidex(ferumoxtran-10)
NanoparticlesSize: 21 nmR1: 17 mMsec-1R2: 48 mMsec-1
![Page 13: Mechanism of Action Combidex in MR Imaging Mukesh Harisinghani, MD Department of Radiology, Massachusetts General Hospital](https://reader030.vdocument.in/reader030/viewer/2022032702/56649ce55503460f949b21a9/html5/thumbnails/13.jpg)
Uptake by normal lymph nodes
Combidex(ferumoxtran-10)
![Page 14: Mechanism of Action Combidex in MR Imaging Mukesh Harisinghani, MD Department of Radiology, Massachusetts General Hospital](https://reader030.vdocument.in/reader030/viewer/2022032702/56649ce55503460f949b21a9/html5/thumbnails/14.jpg)
14
Technique
1.5 T MR systems using pelvic phasearray coil (Siemens Magnetom, GE Horizon)
Imaging time/sequences (25 minutes/patient) T2 FSE sequences T2* gradient echo sequences 3D gradient echo sequences
Post-processing 3D reconstruction
![Page 15: Mechanism of Action Combidex in MR Imaging Mukesh Harisinghani, MD Department of Radiology, Massachusetts General Hospital](https://reader030.vdocument.in/reader030/viewer/2022032702/56649ce55503460f949b21a9/html5/thumbnails/15.jpg)
Pre-contrastPre-contrast Post-contrastPost-contrast
24 hours
![Page 16: Mechanism of Action Combidex in MR Imaging Mukesh Harisinghani, MD Department of Radiology, Massachusetts General Hospital](https://reader030.vdocument.in/reader030/viewer/2022032702/56649ce55503460f949b21a9/html5/thumbnails/16.jpg)
![Page 17: Mechanism of Action Combidex in MR Imaging Mukesh Harisinghani, MD Department of Radiology, Massachusetts General Hospital](https://reader030.vdocument.in/reader030/viewer/2022032702/56649ce55503460f949b21a9/html5/thumbnails/17.jpg)
![Page 18: Mechanism of Action Combidex in MR Imaging Mukesh Harisinghani, MD Department of Radiology, Massachusetts General Hospital](https://reader030.vdocument.in/reader030/viewer/2022032702/56649ce55503460f949b21a9/html5/thumbnails/18.jpg)
20 mm20 mm
![Page 19: Mechanism of Action Combidex in MR Imaging Mukesh Harisinghani, MD Department of Radiology, Massachusetts General Hospital](https://reader030.vdocument.in/reader030/viewer/2022032702/56649ce55503460f949b21a9/html5/thumbnails/19.jpg)
Unenhanced MRUnenhanced MR Combidex enhanced MRCombidex enhanced MR
![Page 20: Mechanism of Action Combidex in MR Imaging Mukesh Harisinghani, MD Department of Radiology, Massachusetts General Hospital](https://reader030.vdocument.in/reader030/viewer/2022032702/56649ce55503460f949b21a9/html5/thumbnails/20.jpg)
20
Clinical Impact
Improved clinical staging
Surgical planning
Radiation therapy planning
Image-guided intervention
![Page 21: Mechanism of Action Combidex in MR Imaging Mukesh Harisinghani, MD Department of Radiology, Massachusetts General Hospital](https://reader030.vdocument.in/reader030/viewer/2022032702/56649ce55503460f949b21a9/html5/thumbnails/21.jpg)
COMBIDEX®COMBIDEX®
(ferumoxtran-10)(ferumoxtran-10)